What are the odds of a serious adverse event from a routine vaccine?
Evidence quality 4.63/5
Eight-dimension review score against the quality rubric . Each dimension scored 1–5.
- D1 Source grounding
- 5/5
- D2 Source authority
- 5/5
- D3 Arithmetic
- 5/5
- D4 Uncertainty
- 4/5
- D5 Scope
- 5/5
- D6 Prose
- 4/5
- D7 Perception honesty
- 4/5
- D8 Caveat completeness
- 5/5
Lifetime probability · lifetime, activity-specific
1 in 763,359
0.0001% lifetime chance
Most people overestimate this.
range 1 in 1,111,111 to 1 in 543,478
● your factors — click this risk ▾ to reveal
≈ As likely as
Perceived
Public perception of vaccine serious adverse event (SAE) rates runs orders of magnitude above the measured numbers, driven by a combination of very vivid individual case reports, the 2020-2022 COVID-mRNA myocarditis signal, and the asymmetry between a population-wide intervention and a background disease most readers never directly see. We have not found a recent rigorous poll that isolates “fear of a serious adverse event from a routine vaccine” from the much broader category of general vaccine hesitancy, so the perceived entry here is editorial intuition, not survey. The directionally robust observation is that when asked to guess SAE rates, readers typically name figures in the low single-digit percent range per dose — roughly three to four orders of magnitude above the measured per-dose rate from the Vaccine Safety Datalink.
Rough estimate: most readers guess the risk at 1 in 100 or worse per dose; measured rates are ~1 in a million for anaphylaxis
Source: editorial intuition, not polled
Actual
~1.31 anaphylaxis cases per million vaccine doses (Vaccine Safety Datalink, 2009-2011)
US patients in the Vaccine Safety Datalink, 2009-2011, all routine vaccines
Show derivation
The headline figure is the anaphylaxis rate from McNeil et al. (JACI 2016), the largest prospective US study of vaccine-triggered anaphylaxis: 33 confirmed cases across 25,173,965 doses in the Vaccine Safety Datalink, for a rate of 1.31 per million doses (95% CI 0.90 to 1.84). We use anaphylaxis as the canonical SAE anchor because it is the best-measured, most consistently defined serious adverse event across the routine vaccine schedule, and because it is the specific “serious” outcome most often invoked in pre-vaccination consent discussions. Scope is declared as activity_specific_lifetime: this is a per-dose probability for the specific activity of receiving a routine vaccine, not a general US-adult-lifetime number, and is not directly comparable to the population-lifetime figures on other Likelier pages. Other measurable SAE signals across the routine schedule sit within the same order of magnitude: Guillain-Barre after influenza vaccine at approximately 1 to 2 additional cases per million doses, historical oral polio vaccine-associated paralytic polio at approximately 1 per 2 to 3 million doses. The notable outlier is post-2021 myocarditis after mRNA COVID-19 second doses in young males, measured at approximately 40.6 per million second doses in males 12 to 29 per the CDC ACIP / Shimabukuro presentation to MMWR in June 2021, with higher rates (62.8 per million) in the 12 to 17 male subgroup. That signal is real and is the subject of the regional_breakdown and caveats sections below; it is also an order of magnitude above the all-vaccine anaphylaxis baseline, which is why Likelier reports both. Almost all measured SAEs resolve without lasting harm: McNeil et al. report zero deaths and only one hospitalization among the 33 anaphylaxis cases.
Caveats: The 1.31 per million headline covers anaphylaxis specifically, which is the best…
The 1.31 per million headline covers anaphylaxis specifically, which is the best-measured SAE across the routine vaccine schedule and the outcome most commonly cited in pre-vaccination consent. It is not a single all-inclusive “any serious adverse event” rate, because the definition of “serious” varies across surveillance systems. Broader aggregate rates of medically-attended serious adverse events across the full US routine schedule run roughly 1 in 100,000 to 1 in 1,000,000 per dose depending on definition, which brackets the anaphylaxis figure. Second caveat: post-2021 mRNA COVID-19 vaccines produced a real, measured elevated myocarditis signal in young males receiving second doses, at approximately 40.6 per million second doses in males 12-29 and up to 62.8 per million in males 12-17 per the CDC ACIP MMWR of June 2021. Likelier publishes real measured numbers, and that signal is real; the clinical follow-up literature (Mevorach et al., Witberg et al., Patone et al.) confirms that the observed cases were overwhelmingly mild and self-resolving with conservative management, but the elevated incidence itself is not in dispute. Third caveat, which is probably the most important comparison Likelier can offer: for every vaccine with a measurable SAE rate, the disease the vaccine prevents has a higher rate of the same SAE. Measles causes myocarditis more often than MMR. SARS-CoV-2 infection causes myocarditis more often than an mRNA second dose, including in young males. Measles case fatality runs roughly 1 per 1,000 in high-income settings, approximately 770 times the MMR anaphylaxis rate. The denominator on “risk of a serious event from a vaccine” is always best understood next to the denominator on “risk of the same serious event from the disease the vaccine prevents.” See <a href="/fears/anaphylaxis-fatal">anaphylaxis-fatal</a> for the related entry on fatal anaphylaxis from all causes.
Regional breakdown
The headline figure averages across very different populations. Here’s how the probability varies by geography or context:
| Region / context | Lifetime probability | Notes |
|---|---|---|
| All routine vaccines, anaphylaxis (VSD, 2009-2011) | 1 in 763,359 |
Headline figure from McNeil et al. JACI 2016. 33 confirmed cases / 25.2 million doses. Zero deaths, 1 hospitalization across all cases. |
| Influenza vaccine, anaphylaxis (inactivated trivalent, alone) | 1 in 740,741 |
10 cases / 7,434,628 doses given alone, per McNeil et al. 1.35 per million, not meaningfully different from the all-vaccine average. |
| mRNA COVID-19 vaccine, myocarditis, males 12-29 (CDC ACIP, June 2021, 2nd dose) | 1 in 24,631 |
40.6 per million second doses per MMWR 70(27). The one routine-schedule SAE signal in the past decade that is meaningfully above the all-vaccine anaphylaxis baseline. Clinical outcomes overwhelmingly mild and self-resolving per follow-up literature. |
| mRNA COVID-19 vaccine, myocarditis, males 12-17 (CDC ACIP, June 2021, 2nd dose) | 1 in 15,924 |
62.8 per million second doses in the highest-signal subgroup. Still below 1 in 10,000 per dose. |
| Influenza vaccine, Guillain-Barre syndrome (excess over background) | 1 in 666,667 |
Approximately 1-2 additional GBS cases per million doses above background, per CDC and post-2009-H1N1 pharmacovigilance studies. Order of magnitude matches the anaphylaxis rate. |
| Oral polio vaccine, vaccine-associated paralytic polio (historical) | 1 in 2,500,000 |
Approximately 1 case per 2-3 million doses of the oral (Sabin) vaccine, the reason the US switched to inactivated (Salk) vaccine in 2000. Included as historical context; the currently-used inactivated polio vaccine does not carry this risk. |
Risks at similar odds
Other risks with roughly the same likelihood — useful for calibration.
Japanese encephalitis (travel)
What are the odds of contracting Japanese encephalitis as a traveler to Asia?
Medication reaction
What are the odds of a serious adverse drug reaction from prescribed medication?
Sudden death (young adult)
What are the odds of dying suddenly as a young, apparently healthy adult?
Recently viewed on this device
Stored locally — clear anytime.
Pick challenger
The best-measured serious adverse event across the US routine vaccine schedule is anaphylaxis, and the canonical US per-dose figure comes from McNeil et al. (JACI 2016), a prospective cohort analysis of the Vaccine Safety Datalink across five health systems from 2009 to 2011: 33 confirmed vaccine-triggered anaphylaxis cases across 25,173,965 doses, for a rate of 1.31 per million doses (95% CI 0.90 to 1.84). Zero of those 33 patients died; one was hospitalized. Other measurable SAE signals across the routine schedule sit within the same order of magnitude: excess Guillain-Barre syndrome after influenza vaccine at roughly 1 to 2 additional cases per million doses, and historical oral polio vaccine-associated paralytic polio at roughly 1 case per 2 to 3 million doses (the reason the US switched to inactivated polio vaccine in 2000). For perspective, the per-million MMR anaphylaxis rate is roughly 770 times lower than the case fatality rate of measles itself, which runs around 1 per 1,000 in high-income settings.
The notable exception to the “low single-digit per million” baseline is the post-2021 myocarditis signal after mRNA COVID-19 second doses in young males. The CDC / ACIP MMWR report of June 2021 put the rate at 40.6 per million second doses in males aged 12 to 29, with higher rates in the 12 to 17 subgroup (62.8 per million). This is a real, measured, replicated signal, and Likelier reports it at face value: roughly 30 times above the all-vaccine anaphylaxis baseline. The clinical follow-up literature from Israel (Mevorach et al., Witberg et al.) and the UK (Patone et al.) confirms both the elevated incidence and the observation that the overwhelming majority of reported cases were mild and self-resolving with conservative management. The elevated incidence itself is not in dispute; the clinical weight of the outcomes is what kept the vaccines in use for the age groups where the infection risk dominated.
The comparison that matters for any of these numbers is the counterfactual. For every vaccine with a measurable SAE rate, the disease the vaccine prevents has a higher rate of the same SAE. Measles causes myocarditis more often than MMR. SARS-CoV-2 infection causes myocarditis more often than an mRNA second dose, including in young males — several cohort studies put the infection-associated myocarditis incidence at six to ten times the vaccine-associated rate in the same age and sex subgroup. The anaphylaxis figure above is itself a small fraction of the all-cause background anaphylaxis rate: see anaphylaxis-fatal for the broader entry on fatal anaphylaxis from all triggers (~205 US deaths per year, of which vaccines are a minority slice). The 1.31 per million headline is not a statement about whether vaccines are safe in the abstract; it is a measurement of a specific, narrowly defined, mostly self-resolving event, published here alongside the one outlier signal (mRNA second-dose myocarditis in young males) that meaningfully departs from it.
Related tidbits
Serious vaccine adverse events: roughly 1-2 per million doses. Unprotected sex STI transmission per encounter: 1-30%. People decline the 1-in-a-million protection while accepting the 1-in-3 exposure.
Claim ledger
Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.
-
[1] Journal of Allergy and Clinical Immunology / McNeil MM, Weintraub ES, Duffy J, et al. (PubMed / NLM) — Risk of anaphylaxis after vaccination in children and adults
Risk of anaphylaxis after vaccination in children and adults- Statistic
33 confirmed vaccine-triggered anaphylaxis cases across 25,173,965 doses in the Vaccine Safety Datalink, 2009-2011; rate of 1.31 per million doses (95% CI 0.90-1.84); zero deaths, one hospitalization- Excerpt
“"We identified 33 confirmed vaccine-triggered anaphylaxis cases that occurred after 25,173,965 vaccine doses. The rate of anaphylaxis was 1.31 (95% CI, 0.90-1.84) per million vaccine doses." ”
- Source data from
- 2016-03-01
- Accessed
- 2026-04-11 · archived copy
- Calculation
- McNeil et al. is a prospective cohort analysis across five Vaccine Safety Datalink sites over 2009-2011. The 33-case numerator divided by the 25,173,965-dose denominator gives the headline rate of ~1.31 per million doses used directly as the native value. Normalized value = numerator / denominator = 33 / 25,173,965 ≈ 1.31 × 10^-6. Uncertainty band uses the paper’s own 95% confidence interval of 0.90 to 1.84 per million, i.e. 9.0 × 10^-7 to 1.84 × 10^-6. Note: incorporating the mRNA myocarditis signal (40.6 per million = 4.06 × 10^-5) would widen the band considerably, but that signal is subgroup- and vaccine-specific and is reported separately in the regional_breakdown. The paper separately reports that all 33 cases recovered, with no deaths and only a single hospitalization, which is the basis for the “resolves without lasting harm in most cases” framing in the long-form body.
- Independence
- VSD-based. Draws on the same five-site cohort that CDC uses for most of its per-dose vaccine safety surveillance. Subsequent reviews (e.g., Dreskin et al. in Current Treatment Options in Allergy 2019) cite this paper as the canonical US per-dose anaphylaxis rate.
-
[2] Morbidity and Mortality Weekly Report / Centers for Disease Control and Prevention — Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021- Statistic
40.6 myocarditis cases reported per million second doses of mRNA COVID-19 vaccine in males aged 12-29; 62.8 per million in males 12-17 and 50.5 per million in males 18-24- Excerpt
“"Myocarditis reporting rates were 40.6 cases per million second doses of mRNA COVID-19 vaccines administered to males aged 12−29 years." ”
- Source data from
- 2021-07-09
- Accessed
- 2026-04-11 · archived copy
- Calculation
- The MMWR report is the ACIP / Shimabukuro presentation that crystallized the myocarditis signal. Used here not as the headline number but as the counter-example that explains why Likelier reports real SAE signals even when they are small. The 40.6 per million figure is approximately 30 times the all-vaccine anaphylaxis baseline of 1.31 per million, which is why the long-form body singles it out: it is the one recent routine-schedule vaccine SAE signal that is meaningfully above the century-average background rate. The same MMWR and follow-up CDC clinical guidance emphasize that the majority of reported myocarditis cases were mild and self-resolving with conservative management, which is what determines how Likelier reports the signal: a real elevated rate, a real clinical follow-up burden, but overwhelmingly mild outcomes.
- Independence
- This is the CDC / ACIP primary surveillance report, drawing on VAERS and V-Safe data which are the US federal vaccine safety monitoring systems. The clinical and cardiology follow-up literature (Mevorach et al. NEJM 2021, Witberg et al. NEJM 2021, Patone et al. Nature Medicine 2022) replicates the signal in independent Israeli and UK datasets, so the effect itself is not a single-source artefact even though the MMWR number is cited here as the US authoritative figure.